Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: A meta-analysis

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1445-1454

  Yang, Lin ^a   Hu, Xin ^a   Xu, Luhang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Acute lymphoblastic leukemia; Meta analysis; Methotrexate; MTHFR; Polymorphism; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLINATE CALCIUM; FOLINIC ACID; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; ANEMIA; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; DIARRHEA; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; ETHNIC DIFFERENCE; GASTROINTESTINAL TOXICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; META ANALYSIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; RISK REDUCTION; SEIZURE; SKIN TOXICITY; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TOXIC HEPATITIS; VOMITING;

EID: 84868148325     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0395-2     Document Type: Article

References (55)

1. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Pinan MA, Garcia-Miguel P, Navajas A, Garcia-Orad A. Polymorphisms of the slco1b1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57:612-9.
2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535-48.
3. Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007;109:4151-7.
4. Tantawy AA, El-Bostany EA, Adly AA, Abou El Asrar M, El-Ghouroury EA, Abdulghaffar EE. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2010;21:28-34.
5. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA. 1999;96:12810-5.
6. Narayanan S, McConnell J, Little J, Sharp L, Piyathilake CJ, Powers H, Basten G, Duthie SJ. Associations between two common variants c677t and a1298c in the methylenetetrahydrofolate reductase gene and measures of folate metabolism and DNA stability (strand breaks, misincorporated uracil, and DNA methylation status) in human lymphocytes in vivo. Cancer Epidemiol Biomarkers Prev. 2004;13:1436-43.
7. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-3.
8. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet. 1998;62:1044-51.
9. Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, Mini E, Boiocchi M. Effect of methylenetetrahydrofolate reductase 677c->t polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer. 2003;103:294-9.
10. Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E, Yamanaka M, Yamanaka H, Kamatani N. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics. 2007;17:383-90.
11. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, Ariail KS, Keener CL, Li S, Liu H, Farin FM, Potter JD. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase c677t polymorphism. Blood. 2001;98:231-4.
12. Chiusolo P, Reddiconto G, Casorelli I, Laurenti L, Sora F, Mele L, Annino L, Leone G, Sica S. Preponderance of methylenetetrahydrofolate reductase c677t homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol. 2002;13:1915-8.
13. Ongaro A, De Mattei M, Della Porta MG, Rigolin G, Ambrosio C, Di Raimondo F, Pellati A, Masieri FF, Caruso A, Catozzi L, Gemmati D. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica. 2009;94:1391-8.
14. Karathanasis NV, Stiakaki E, Goulielmos GN, Kalmanti M. The role of the methylenetetrahydrofolate reductase 677 and 1298 polymorphisms in cretan children with acute lymphoblastic leukemia. Genet Test Mol Biomarkers. 2011;15:5-10.
15. Ruiz-Arguelles GJ, Coconi-Linares LN, Garces-Eisele J, Reyes-Nunez V. Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico. Hematology. 2007;12:387-91.
16. van Kooten Niekerk PB, Schmiegelow K, Schroeder H. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate. Eur J Haematol. 2008;81:391-8.
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS Med. 2009;6:e1000097.
20. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, Takeshima Y, Sakaeda T, Matsuo M, Okumura K. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52:166-71.
21. Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolzan V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol. 2011;67:993-1006.
22. Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N, Topcuoglu N, Aksoylar S, Cinar M, Tetik A, Eroglu Z. Methylenetetrahydrofolate reductase c677t and a1298c gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Leuk Lymphoma. 2009;50:912-7.
23. Taub JW, Matherly LH, Ravindranath Y, Kaspers GJ, Rots MG, Zantwijk CH. Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. Leukemia. 2002;16:764-5.
24. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2004;4:66-72.
25. Nowak-Gottl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, Schwabe D, Ehrenforth S. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 1999;93:1595-9.
26. Jazbec J, Kitanovski L, Aplenc R, Debeljak M, Dolzan V. No evidence of association of methylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms after treatment of childhood leukemia. Leuk Lymphoma. 2005;46:893-7.
27. Chatzidakis K, Goulas A, Athanassiadou-Piperopoulou F, Fidani L, Koliouskas D, Mirtsou V. Methylenetetrahydrofolate reductase c677t polymorphism: association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in Greek patients. Pediatr Blood Cancer. 2006;47:147-51.
28. Karas Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I. 5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL). Leuk Res. 2009;33:1344-8.
29. Krajinovic M, Robaey P, Chiasson S, Lemieux-Blanchard E, Rouillard M, Primeau M, Bournissen FG, Moghrabi A. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics. 2005;6:293-302.
30. Kamdar KY, Krull KR, El-Zein RA, Brouwers P, Potter BS, Harris LL, Holm S, Dreyer Z, Scaglia F, Etzel CJ, Bondy M, Okcu MF. Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy. Pediatr Blood Cancer. 2011;57:454-60.
31. Salazar J, Altes A, Del Rio E, Estella J, Rives S, Tasso M, Navajas A, Molina J, Villa M, Vivanco JL, Torrent M, Baiget M, Badell I (2012) Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J. doi: 10.1038/tpj.2011.25
32. El-Khodary NM, El-Haggar SM, Eid MA, Ebeid EN (2012) Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol. doi: 10.1007/s12032-011-9997-6
33. Costea I, Moghrabi A, Laverdiere C, Graziani A, Krajinovic M. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica. 2006;91:1113-6.
34. Xu KK, Liao QC, Zhang Y, Xu J, Luo L, Wang CX, Peng XX. Influence of MTHFR C677T and RFC1 G80A gene polymorphisms on adverse reactions of high dose methotrexate chemotherapy in children with acute lymphoblastic leukemia. J Appl Clin Pediatr. 2009;24:1674-6.
35. Xu H, Zhang YN, Kang XX. The relationship between methylenetetrahydrofolate reductase gene polymorphism and serum concentration of methotrexate in children with acute lymphoblastic leukemia. Chin J Lab Diagn. 2010;14:676-9.
36. Li TY, Wang B, Xu KK, Xu J, Gu HJ, Liao QC, Yang L, Yan HL. Polymorphism C677T in methylenetetrahydrofolate reductase gene and its relationship to methotrexate-induced toxicities of childhood acute lymphoblastic leukemia. Acta Univ Med Nanjing (Nat Sci). 2010;30:386-9, 404.
37. Liu SG, Li ZG, Cui L, Gao C, Li WJ, Zhao XX. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population. Leuk Lymphoma. 2011;52:1030-40.
38. Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I. Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood all patients. Leukemia. 2009;23:971-4.
39. Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, Torii C, Yoshihara H, Tanigawara Y, Takahashi T, Kosaki K. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2006;28:64-8.
40. Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B, Rebbeck T. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. 2005;65:2482-7.
41. Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, Hudson M, Rubnitz J, Sandlund JT, Pui CH, Relling MV. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003;21:3084-91.
42. D'Angelo V, Ramaglia M, Iannotta A, Crisci S, Indolfi P, Francese M, Affinita MC, Pecoraro G, Napolitano A, Fusco C, Oreste M, Indolfi C, Casale F. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol. 2011;68(5):1339-46.
43. Chiusolo P, Reddiconto G, Farina G, Mannocci A, Fiorini A, Palladino M, La Torre G, Fianchi L, Sora F, Laurenti L, Leone G, Sica S. MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res. 2007;31:1669-74.
44. Shimasaki N, Mori T, Torii C, Sato R, Shimada H, Tanigawara Y, Kosaki K, Takahashi T. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008;30:347-52.
45. Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia. 2008;22:1798-800.
46. Krull KR, Brouwers P, Jain N, Zhang L, Bomgaars L, Dreyer Z, Mahoney D, Bottomley S, Okcu MF. Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. J Pediatr. 2008;152:101-5.
47. Liu JX, Chen JP, Tan W, Lin DX. Association between MTHFR gene polymorphisms and toxicity of HDMTX chemotherapy in acute lymphocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16:488-92.
48. Toffoli G, Veronesi A, Boiocchi M, Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2000;11:373-4.
49. Tukova J, Chladek J, Hroch M, Nemcova D, Hoza J, Dolezalova P. 677TT genotype is associated with elevated risk of methotrexate (MTX) toxicity in juvenile idiopathic arthritis: treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms. J Rheumatol. 2010;37:2180-6.
50. Caliz R, Del Amo J, Balsa A, Blanco F, Silva L, Sanmarti R, Martinez F, Collado M, Ramirez Mdel C, Tejedor D, Artieda M, Pascual-Salcedo D, Oreiro N, Andreu J, Graell E, Simon L, Martinez A, Mulero J. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scand J Rheumatol. 2012;41:10-4.
51. Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 2006;54:1087-95.
52. Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol. 2009;36:539-45.
53. Spyridopoulou KP, Dimou NL, Hamodrakas SJ, Bagos PG. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis. Pharmacogenet Genomics. 2012;22:117-33.
54. Toffoli G, De Mattia E. Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics. 2008;9:1195-206.
55. Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, Udomsubpayakul U, Sirachainan N, Thithapandha A, Hongeng S. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol. 2007;86:609-11.